Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
about
Filoviral immune evasion mechanismsDRBP76 associates with Ebola virus VP35 and suppresses viral polymerase functionMutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcomeStructural and Functional Characterization of Reston Ebola Virus VP35 Interferon Inhibitory DomainStructure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppressionMarburg Virus VP35 Can Both Fully Coat the Backbone and Cap the Ends of dsRNA for Interferon AntagonismStructural basis for Marburg virus VP35-mediated immune evasion mechanismsThe Ebola Virus Interferon Antagonist VP24 Directly Binds STAT1 and Has a Novel, Pyramidal FoldEbolavirus VP35 Coats the Backbone of Double-Stranded RNA for Interferon AntagonismDevelopment of RNA Aptamers Targeting Ebola Virus VP35In Silico Derived Small Molecules Bind the Filovirus VP35 Protein and Inhibit Its Polymerase Cofactor ActivityStructural and mechanistic insights into human splicing factor SF3b complex derived using an integrated approach guided by the cryo-EM density mapsModeling of the Ebola virus delta peptide reveals a potential lytic sequence motifInvestigating Engineered Ribonucleoprotein Particles to Improve Oral RNAi Delivery in Crop Insect Pests.Recognition of virus infection and innate host responses to viral gene therapy vectors.Detecting remote sequence homology in disordered proteins: discovery of conserved motifs in the N-termini of Mononegavirales phosphoproteinsInterplay between innate immunity and negative-strand RNA viruses: towards a rational modelMolecular mechanisms of viral inhibitors of RIG-I-like receptors.Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses.How Ebola virus counters the interferon system.Camouflage and misdirection: the full-on assault of ebola virus diseaseEbolavirus VP35 is a multifunctional virulence factor.Characterizing alpha helical properties of Ebola viral proteins as potential targets for inhibition of alpha-helix mediated protein-protein interactions.Innate immune evasion by filovirusesThe role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge.Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 ComplexDifferent Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.Immunological features underlying viral hemorrhagic feversPredictive and comparative analysis of Ebolavirus proteinsUsing hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A2 superfamily with lipid substrates, inhibitors, and membranes.Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses.Ebola virus does not block apoptotic signaling pathways.Ebola Virus Does Not Induce Stress Granule Formation during Infection and Sequesters Stress Granule Proteins within Viral Inclusions.Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist.Crystal Structure of the Marburg Virus VP35 Oligomerization Domain.Sensing microbial RNA in the cytosol.Characterization of host immune responses in Ebola virus infections.Viral proteins that bind double-stranded RNA: countermeasures against host antiviral responses.Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus
P2860
Q22305519-0F0433D8-7682-41B9-89B2-43B5F5D1AF72Q24292964-21D7C14E-A563-40C4-A55A-5F3E90E05E51Q24310145-A262E19E-7FA9-49D9-B87B-EE39020B7643Q27660589-CC6233B3-AE26-4DE9-A7E6-C5A114A46609Q27666703-E67E1D90-A020-4DC0-8E54-4187F5CEE02BQ27673907-B42E6245-3AEE-414D-9775-89C91BE9C7FEQ27675266-427EC8A9-710E-4182-B305-BB965100F24CQ27677595-8095796F-45EC-4E68-8556-A54889B590A2Q27678917-A92A2973-8707-4E6E-9EF7-7AADF714BA62Q27680060-EFC76328-0983-4D86-B528-FFB18B28C412Q27681581-CB47D0E6-C773-4269-B8EB-4CC9C29C7F7AQ28315106-71E12F2C-4062-4227-983E-BDEFAEC2F1BAQ28651528-FDAF9436-CD9F-448D-B259-D4A34E5353C7Q30847165-EC3D0D20-2898-4CDC-9023-8A849357ED87Q34080884-B88D2542-57F0-42F6-B508-A865BE6B8648Q34189305-C2E281DB-F4E1-49CF-A9E1-70EBA3D73385Q34212787-14AF9F02-83E0-410D-BD49-4B9989E803A9Q34253570-8258C11E-7245-4A55-8FD4-8235B5E8810DQ34266468-BD97EFF3-FC3D-4C2C-8BAD-74C1E1259B89Q34298213-89EB30AE-5C45-4D8E-9117-D9F657E72E26Q34449079-3601B666-BAC4-4B1C-9A5A-3B8578650B8DQ34700463-C669DD7E-F463-4546-BC84-0776548F61F1Q35086957-130186C5-1E6E-406E-81E4-2192325F5E54Q35582244-55E0CA80-D4D7-41EA-A6E8-E2CBA8CEC359Q35823426-6DC56213-FCD4-4875-BBD2-3047C47EAE38Q35846673-9BDEABEC-7120-4F06-9F50-DDB4301C8ABAQ35861130-A315646B-C72D-4D2D-9A2D-F9CBC0A51B42Q36122433-DAE4CA14-563A-44BD-8F84-61D1B36BCBFCQ36189492-511EF395-F2C4-4E16-BDD4-42427B3184F6Q36543771-51CDDE96-CEC3-43F6-AD4F-4126FF6AE695Q36619514-2391CBC5-E1C2-47E9-819A-2973FA2000BAQ36724747-C7325CAD-D636-4FD6-AACA-9463C3520687Q36827365-F6C53230-D71C-48E5-ADD0-1B37C5362E57Q37174456-C3CA6F78-9EEC-4D39-9126-CF335A2D1560Q37254398-2EA10F48-DC14-4FA9-BEB5-FDD6FBA0C23FQ37560760-CE241A63-FA00-4B26-995E-E8C301AC6468Q38176612-24909B82-24F1-409B-8842-45EB76FDE897Q38205274-FB8E023D-9B4D-4D60-A9D1-C32C0FF00650Q38218190-C31DF350-DA0E-4077-99D6-45B5EF2DD066Q38599899-C9247229-8105-499F-A0E3-BF12CAD15499
P2860
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@ast
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@en
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@nl
type
label
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@ast
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@en
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@nl
prefLabel
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@ast
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@en
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@nl
P2093
P2860
P3181
P356
P1476
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression
@en
P2093
Christopher R Kimberlin
Ian J MacRae
Virgil L Woods
Zachary A Bornholdt
P2860
P3181
P356
10.1073/PNAS.0910547107
P407
P577
2010-01-05T00:00:00Z